Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Novel approach to estimate transmission advantage of SARS-CoV-2 variants in real-time

A new study retrospectively estimates the effective transmission advantage of the Alpha variant as compared to other non-VOC lineages.

1 Dec 2021

Impact of partial lockdown on breaking COVID-19 fourth wave in Bavaria

An agent-based simulator was used to determine the historical course of COVID-19 and to analyze the effectiveness of lockdown.

1 Dec 2021

Plant-derived virus-like particle vaccines against SARS-CoV-2

In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.

1 Dec 2021

Impact of SARS-CoV-2 on oral health

New research examined SARS-CoV-2 and its impact on oral health and suggests that survival against the infection may be partially dependent on such factors.

1 Dec 2021

Nanoengineers develop a new approach to effectively deliver mRNA into cells

Nanoengineers at the University of California San Diego have developed a new and potentially more effective way to deliver messenger RNA (mRNA) into cells.

30 Nov 2021

Review highlights oncolytic viruses with remarkable ability to destroy cancer cells

With the world still in the grip of a devastating pandemic, it's hard to imagine viruses as something other than hostile enemies to be vanquished.

30 Nov 2021

Natural COVID-19 infection offers protection from gamma and delta variants of SARS-CoV-2

Natural infection with COVID-19 offered protection from reinfection when the gamma and delta variants predominated, according to a new University of Michigan study that also provides levels of antibodies needed to protect against reinfections.

30 Nov 2021

Northwestern researchers continue to tackle every facet of COVID-19 pandemic

As the COVID-19 pandemic nears the two-year mark, Northwestern Medicine scientists continue to tackle every facet of the disease, from investigating coronavirus vaccines' potential for providing immunity against similar coronaviruses to developing novel rapid antigen-based tests and examining disparities in COVID-19 case and mortality rates in Chicago.

30 Nov 2021

COVID-19 booster jabs to be offered to all adults in England by the end of January

All eligible adults in England aged 18 and over will be offered a COVID-19 booster vaccine by the end of January.

30 Nov 2021

Omicron and other coronavirus variants: What you need to know

Americans, already weary of a pandemic nearly two years long, were dealt a new blow during the long Thanksgiving weekend: the announcement that a new coronavirus variant had emerged.

30 Nov 2021

Prior infection with SARS-CoV-2 continues to provide protection from reinfection

Researchers from the University of Michigan investigated the correlation between SARS-CoV-2 infection and the severity of reinfections.

30 Nov 2021

Scientists develop a smartwatch-based device for early detection of COVID-19

Scientists have developed a wearable device that can detect the early onset of COVID-19 in real-time by analyzing the aberrant changes in physiological parameters caused by SARS-CoV-2 infection.

30 Nov 2021

UK study finds COVID-19 from Delta and Alpha infections are clinically similar

Research suggests that COVID-19 from Delta or Alpha infections is clinically similar, yet Delta is more transmissible than Alpha.

30 Nov 2021

With federal covid sick leave gone, workers feel pressure to show up at work

Economists and public health experts alike say paid sick leave is an essential tool — like testing, masks and vaccines — in the effort to prevent covid-19 infection and keep workplaces safe.

30 Nov 2021

Anti-SARS-CoV-2 antibodies suggested to be safe to use in pregnancy

Pregnant patients with mild to moderate COVID-19 were treated with MAb and reported no adverse effects.

30 Nov 2021

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.

29 Nov 2021